International Diabetes Center

About

We focus on translating new findings into clinical practice and discovering innovative ways to use technology to improve diabetes care.

Affiliation

people

Faculty Position
  • Bergenstal, Richard M., MD, Executive Director, International Diabetes Center 1983 -
  • Carlson, Anders L., MD, Medical Director, International Diabetes Center 2015 -
  • Criego, Amy B., MD, MS, Medical Director of International Diabetes Center
  • Johnson, Mary L. , Director, Administration and Clinical Research
  • Martens, Thomas W., MD, FACP, Medical Director, International Diabetes Center 2015 -

    • Publications While At HealthPartners

    selected publications

    Journal Article
  • "Now I can see it works!" Perspectives on using a nutrition-focused approach when initiating continuous glucose monitoring in people with type 2 diabetes: qualitative interview study. 
    JMIR diabetes. 2025
    Article has an altmetric score of 1
  • A call-to-action to eliminate barriers to accessing automated insulin delivery systems for people with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2025
    Article has an altmetric score of 14
  • A randomized controlled trial using continuous glucose monitoring to guide food choices and diabetes self-care in people with type 2 diabetes not taking insulin. 
    Diabetes Technology & Therapeutics. 2025
    Article has an altmetric score of 1
  • Automated insulin delivery in adults with type 2 diabetes: a nonrandomized clinical trial. 
  • Continuous glucose monitoring-based titration of once-weekly insulin icodec in insulin-naive individuals with type 2 diabetes (onwards 9): a phase 3b, multicenter, single-arm, treat-to-target clinical trial. 
    Diabetes Technology & Therapeutics. 2025
    • Editorial Article
  • The Glucose Management Indicator: time to change course [editorial]?. 
  • Continuous glucose monitoring for type 2 diabetes: how does it compare with type 1 diabetes [editorial]?. 
  • More green, less red: how color standardization may facilitate effective use of CGM data [editorial]. 
  • Continuous glucose monitoring-derived data report-simply a better management tool [editorial]. 
  • Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes [editorial]. 
    • Conference Paper
  • Diabetes technology in 2019 [invited speaker]
    2019
  • Diabetes technology in clinical practice [invited speaker]
    2018
  • The connection between dementia and diabetes [invited speaker]
    2017
  • Diabetes technology: beyond insulin pumps [invited speaker]
    2016
    • Conference Poster
  • Autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D Exchange [poster]
    2019
  • Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care [poster]
    2019
  • Hybrid closed-loop in adults with type 1 diabetes: impact of baseline A1c on glucose outcomes and insulin delivery [poster]
    2019
  • Low level of agreement in evaluation of continuous glucose monitoring profiles [poster]
    2019
  • Optimal sampling duration of hybrid closed-loop therapy to determine long-term glycemic control in adults with type 1 diabetes [poster]
    2019
    • Report
  • Diagnosis and managment of type 2 diabetes mellitus in adults [health care guideline]
    2009
  • Diagnosis and managment of type 2 diabetes mellitus in adults [health care guideline]
    2008
    • Review
  • Effective strategies for the prevention and mitigation of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia: optimizing patient care [review]. 
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2025
  • Decreasing the burden of carbohydrate counting and meal announcement with automated insulin delivery, meal recognition, and autocorrection doses: a case study [review]. 
  • Is it time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes [review]. 
  • Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme [review]. 
    • Abstract
  • Evaluation of race and ethnicity and pharmacy dispensing of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes [abstract]. 
    Circulation. 2024
  • Change in A1C with and without intermittent use of CGM in adults with type 2 diabetes participating in the Onduo Virtual Diabetes Clinic [abstract]. 
    Diabetes. 2020
  • Cross-study comparisons done right: an illustration using two pivotal trials of closed-loop systems [abstract]. 
    Diabetes. 2020
  • Derived time-in-range is associated with MACE in T2D: data from the DEVOTE Trial [abstract]. 
    Diabetes. 2020
  • First home evaluation of the Omnipod Horizon automated glucose control system at specific glucose targets in children with type 1 diabetes [abstract]. 
    Diabetes. 2020
    • Audio Document
  • CGM use in type 2 diabetes
    2018
    • Patent
  • Methods for treating patients with impaired awareness of hypoglycemia
    2021
  • Treatment of hypoglycemia unawareness with intranasal insulin
    2017
    • Webpage
  • Will the surge in new diabetes devices improve patient outcomes?
    2020

    • Quick Info